# 王照元教授 (Jaw-Yuan Wang, MD, PhD)


- 中華民國大腸直腸外科醫學會理事長
- 高雄醫學大學附設中和紀念醫院 臨床醫學研究部主任
- 高雄醫學大學附設中和紀念醫院 臨床醫學研究部/人體生物資料庫主任
- 高雄醫學大學教授

- Email：jayuwa@cc.kmu.edu.tw


## Biography

Prof. Jaw-Yuan Wang is Professor of the Department of Surgery, Faculty of Medicine and Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Since 2018 he hold the position of President of the Society of Colon and Rectal Surgeons, Taiwan. Between 2014 and 2020, he has been Vice superintendent at Kaohsiung Medical University Hospital. He went on to receive further training as a Research Fellow at the State University of New York, Stony Brook, USA. He now serves as Leader of Colorectal Cancer Multidisciplinary Team, Program Director of Robotic Surgery, Chairman of Nutrition Support Council, Kaohsiung Medical University Hospital, Kaohsiung Medical University. He is an active member in numerous professional organizations including the Taiwan Surgical Association, Taiwan Surgical Society of Gastroenterology, Society of Colon and Rectal Surgical Society of Gastroenterology, Taiwan; Taiwan Robotic Surgery Association; Taiwan Society of Parenteral and Enteral Nutrition, Taiwan Oncology Society, Clinical Oncology Society of Taiwan, Parenteral and Enteral Nutrition of Asia, International Association of Surgeons and Gastroenterologists, A, The Academy of Surgical Research and The Chinese Oncology Society. He also holds appointments as President of Colon and Rectal Surgeons, Taiwan; director of board of Taiwan Society of Coloproctology; executive director of board of Taiwan Society of Parenteral and Enteral Nutrition and executive director of board of Taiwan Genomic Medicine and Biomarker Society. Besides being a recipient of numerous awards since 2003, he has published widely at least 332 peer-reviewed papers (274 SCI and 58 Non-SCI) and 5 book chapters. Prof. Wang is an editor in several prestigious international Journals, e.g World Journal of Gastroenterology, Asian Journal of Surgery, Kaohsiung Journal of Medical Sciences (Associate Editor), Oncology Letters and Frontiers in Oncology (Guest Associate Editor). As a reviewer for more than 70 prestigious journals including Annals of Surgery, Gastroenterology, Cancer Research, Oncology, American College of Surgeons, BMC Cancer, Cancer Letters, Clinical Cancer Research, Expert Review of Molecular Diagnostics, International Journal of Cancer and British Journal of Cancer etc. He has also been the PI of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, between 2012 and 2018. Since 2019, he was appointed as clinical implication committee member, Taiwan Precision Medicine Initiative, Academia Sinica, Taiwan.

## Education Background：

- 高雄醫學院醫學系
- 高雄醫學院醫學研究所碩士
- 高雄醫學大學醫學研究所博士

## Professional Experience：

- 高雄醫學大學醫學研究所碩士班主任
- 高雄醫學大學實驗外科學主任
- 高雄醫學大學附設中和紀念醫院小兒外科主任
- 高雄醫學大學附設中和紀念醫院營養支援小組 主任
- 高雄醫學大學臨床醫學研究所所長
- 高雄醫學大學附設中和紀念醫院 副院長

## Latest Selected Publications：


1. Chuang YP, **Wang JY**, Jao SW, Wu CC, Chen JH, Hsiao KH, Lin CY, Chen SH, Su SY, Chen YJ, Chen YT, Wu DC, Li LH. Over-expression of *AURKA*, *SKA3* and *DSN1* contributes to colorectal adenoma to carcinoma progression. Oncotarget. 2016. MOST104-2325-B-037-001, MOHW105- TDU-B-212-134007, Health and welfare surcharge of tobacco products, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.
2. Yang IP, Tsai HL, Huang CW, Lu CY, Miao ZF, Chang SF, Juo SH, **Wang JY***. High Blood Sugar Levels Significantly Impact the Prognosis of Colorectal Cancer Patients through Down-regulation of MicroRNA-16 by Targeting *Myb* and *VEGFR2*. Oncotarget. 2016 Feb 25. MOST103-2314-B-037-010-MY3, MOHW105-TDU-B-212-134005, Health and welfare surcharge of tobacco products, KMUH102-2M46, KMUH103-3M39**,** KMU-TP104C00, KMU-TP104C01, KMU-TP104C02, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. **(**Category: Oncology, IF: 6.359, Ranking: 21/211, 2014 JCR**).**
3. Yang IP, Tsai HL, Miao ZF, Huang CW, Kuo CH, Wu JY, Wang WM, Juo SH, **Wang JY***. Development of a Deregulating microRNA Panel for the Detection of Early Relapse in Postoperative Colorectal Cancer Patients. J Transl Med 2016 Apr 29;14(1):108. (MOHW105-TDU-B-212-134007), (KMU-TP104C00, KMU-TP104C03, KMU-TP104C04, KMU-TP104C07, KMU-TP104A11, KMU-PT10422, KMU-DK105001); (MOST104-2325-B-037-001); (KMUH103-3M39; KMUH103-3M58; KMUH104-4M51); and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. **(**Category: Medicine, Research & Experimental, IF: 3.930, Ranking: 26/123, 2014 JCR**).**
4. Kan JY, Yen MC, **Wang JY**, Wu DC, Chiu YJ, Ho YW, Kuo PL. Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer. Oncotarget. 2016 May 2.
5. Su WC, Tsai HL, Yeh YS, Huang CW, Chen FM, **Wang JY***. Successful Management of Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Three Case Reports and Literature Review. J Soc Colon Rectal Surgeon (Taiwan) 2016;27:83-89.

6. Chen YT, Tsao SC, Tsai HP, **Wang JY**, Chai CY. Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy. J Clin Pathol. 2016 Apr 22.
7. Huang CW, Yeh YS, Ma CJ, Tsai HL, Chen CW, Huang MY, Lu CY, Wu JY, **Wang JY***. Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as a First-Line Treatment. Chemotherapy (Accepted in 2016). MOST104-2325-B-037-001); (MOHW 105-TDU-B-212-134007), (KMUH104-4M29, KMUH104-4R19, KMUH-S10415, KMUH-S10418,); (KMU-TP104C00, KMU-TP104C03, KMU-TP104C04, KMU-TP104C07, KMU-TP103H10, KMU-TP103H11, KMU-PT104002, KMU-DK105001, D08-00005-10401); (KMU-TP104A11), and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.
8. Huang CW, Yeh YS, Su WC, Tsai HL, Choy TK, Huang MY, Huang CM, Wu IC, Hu HM, Hsu WH, Su YC, **Wang JY***. Robotic Surgery with High Dissection and Low Ligation Technique for Consecutive Patients with Rectal Cancer Following Preoperative Concurrent Chemoradiotherapy. Int J Colorectal Dis 2016 Jun;31(6):1169-77. MOHW105-TDU-B-212-134007, KMU-TP104C00, KMU-TP104C03, KMU-TP104C04, KMU-TP104C07, KMU-TP104A11, KMU-PT10422, KMU-DK105001; MOST104-2325-B-037-001; KMUH103-3M39; KMUH103-3M58; KMUH104-4M51; and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. **(**Category: Surgery, IF: 2.449, Ranking: 55/198, 2014 JCR**).**
9. Tsai HL, Huang CW, Chen CW, Yeh YS, Ma CJ, **Wang JY***. Survival in Resected Stage II Colorectal Cancer Is Dependent on Tumor Depth, Vascular Invasion, Postoperative CEA Level, and The Number of Examined Lymph Nodes. World J Surg 2016 Apr;40(4):1002-9. **(**Category: Surgery, IF: 2.642, Ranking: 47/198, 2014 JCR**).** MOST104-2325-B-037-001; MOHW 104-TDU-B-212-124-003, KMUH100-OM16, KMUH103-3R16, KMUHS10304,KMUHS10305; KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11, KMU-TP104A11); and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.
10. Chen YT, Tsao SC, Tsai HP, **Wang JY**, Chai CY. The X-linked inhibitor of apoptosis protein is an independent prognostic marker for rectal adenocarcinoma after preoperative chemoradiotherapy. Virchows Arch 2016 Feb 25. **(**Category: Pathology, IF: 2.651, Ranking: 23/76, 2014 JCR**).**
11. Yeh YS, Tsai HL, Huang CW, Wang JH, Lin YW, Tang HC, Sung YC, Wu CC, Lu CY, **Wang JY***. Prospective analysis of *UGT1A1* promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial. Trials 2016 Jan 25;17(1):46. MOST103-2314-B-037-010-MY3, MOHW105-TDU-B-212-134005, Health and welfare surcharge of tobacco products, KMUH102-2M46, KMUH103-3M39**,** KMU-TP104C00, KMU-TP104C01, KMU-TP104C02. **(**Category: Medicine, Research & Experimental, IF: 1.731, Ranking: 81/123, 2014 JCR**).**
12. Huang MY, Huang CM, Tsai HL, Huang CW, Hsieh HM, Yeh YS, Wu JY, Wang WM, **Wang JY***. Comparison of adjuvant FOLFOX4 chemotherapy versus oral UFT/LV following adjuvant FOLFOX4 chemotherapy in stage III colon cancer patients after radical resection**.** Oncology Letters 2015 (Accepted), MOST103-2314-B-037-010-MY3, MOHW 104-TDU-B-212-124-003, KMUH103-3M03, KMUHS10418, KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11. **(**Category: Oncology, IF: 1.554, Ranking: 173/211, 2014 JCR**).**
13. Lu CY, Huang CW, Wu IC, Tsai HL, Ma CJ, Yeh YS, Chang SF, Huang ML, **Wang JY***. Clinical Implication of *UGT1A1* Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting. Transl Oncol 2015 Dec;8(6):474-

9. MOST103-2314-B-037-010-MY3, MOHW 104-TDU-B-212-124-003, KMUH102-2M46, KMUH103-3M39**,** KMU-TP104C00, KMU-TP104C01, KMU-TP104C02. **(**Category: Oncology, IF: 2.884, Ranking: 105/211, 2014 JCR**).**

14. **Wang JY**, Sun J, Huang MY, Wang YS, Hou MF, Sun Y, He H, Krishna N, Chiu SJ, Lin S, Yang S, Chang WC*. STIM1 Overexpression Promotes Colorectal Cancer Progression, Cell Motility and COX-2 Expression. Oncogene 2015 Aug 13;34(33):4358-67. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, KMU-TP103C03. **SCI**. (Category: Oncology, IF: 8.459, Ranking: 13/211, 2014 JCR).
15. Chen KC, Liao YC, **Wang JY**, Lin YC, Chen CH, Juo SH. Oxidized low-density lipoprotein is a common risk factor for cardiovascular diseases and gastroenterological cancers via epigenomical regulation of microRNA-210. Oncotarget 2015 Sep 15;6(27):24105-18. **SCI**. (Category: Oncology, IF: 6.359, Ranking: 21/211, 2014 JCR).
16. Huang CC, Kuo KK, Cheng TC, Chuang CH, Kao CH, Hsieh YC, Cheng KH, **Wang JY**, Cheng CM, Chen CS, Cheng TL. Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine. PLoS One. 2015 Jul 17;10(7):e0133470. **SCI.** (Category: Multidisciplinary Sciences, IF: 3.234, Ranking: 8/56, 2014 JCR).
17. Huang CW, Tsai HL, Huang MY, Huang CM, Yeh YS, Ma CJ, **Wang JY***. Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer. World J Surg Oncol. 2015 Aug 28;13:257. **SCI**. (Category: Surgery, IF=1.408; Ranking: 107/198, 2014 JCR).
18. Lou YT, Chen CW, Fan YC, Chang WC, Lu CY, Wu IC, Hsu WH, Huang CW, **Wang JY***. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. PLoS One. 2015 Apr 28;10(4):e0123973. **SCI.** (Category: Multidisciplinary Sciences, IF: 3.234, Ranking: 8/56, 2014 JCR).
19. Yeh YS, Huang YH, Lin HC, Shih YL, Lu CY, **Wang JY***. J Gastrointest Dig Syst S Long-Term Recurrent Liposarcoma of the Mediastinum with Gastric Metastasis: A Case Report. 2015;S13:1.
20. Huang CW, Yeh YS, Ma CJ, Choy TK, Huang CM, Hsu WH, **Wang JY***. Robotic colorectal surgery for laparoscopic surgeons with limited experience: Preliminary experiences for 40 consecutive cases at a single medical center. BMC Surg 2015 Jun 18;15:73. MOST103-2325-B-037-005, MOHW103-TD-B-111-05, KMUH103-3R16, KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. (Category: Surgery, IF=1.397; Ranking: 108/198, 2014 JCR).
21. Kan JY, Wu DC, Yu FJ, Wu CY, Ho YW, Chiu YJ, Jian SF, Hung JY, **Wang JY***, Kuo PL*. Chemokine (C-C motif) ligand 5 is involved in tumor-associated dendritic cell-mediated colon cancer progression through noncoding RNA MALAT-1. J Cell Physiology 2015 Aug;230:1883-94. **SCI**. (Category: Physiology, IF=3.839; Ranking: 15/83, 2014 JCR). (Equally contributed corresponding author).
22. Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, **Wang JY***. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol 2015 Feb 1;8(2):1900-10. **SCI.** (Category: Pathology, IF=1.895; Ranking: 40/75, 2014 JCR).
23. Lee YC, Yin TC, Chen YT, Chai CY, **Wang JY**, Liu MC, Lin YC, Kan JY. High Expression of Phospho-H2AX Predicts a Poor Prognosis in Colorectal Cancer. Anticancer Res 2015 Apr;35:2447-53. **SCI**. (Category: Oncology, IF: 1.826, Ranking: 162/211, 2014 JCR).

24. Huang MY, Lin CH, Huang CM, Tsai HL, Huang CW, Yeh YS, Chai CY, **Wang JY***. Relationships between SMAD3 Expression and Preoperative Fluoropyrimidine-Based Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients. World J Surg 2015 May;39(5):1257-67. MOST103-2325-B-037-005 and MOHW 104-TDU-B-212-124-003, KMUH103-3R16, KMUHS10304, KMUHS10305, KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-TP103H11, and the Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. **SCI.** (Category: Surgery, IF=2.642; Ranking: 47/198, 2014 JCR).
25. Ma CJ, Wu JM, Tsai HL, Huang CW, Lu CY, Sun LC, Shih YL, Chen CW, Chuang JF, Wu MH, Wang MY, Lin MS, **Wang JY***. Prospective Double-Blind Randomized Study on the Efficacy and Safety of an n-3 Fatty Acid enriched intravenous fat emulsion in Postsurgical Gastric and Colorectal Cancer Patients. Nutr J 2015 Jan 21;14:9. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan, KMU-TP103C00. **SCI.** (Category: Nutrition & Dietetics, IF=2.597; Ranking: 36/77, 2014 JCR).
26. Kao CH, **Wang JY**, Chuang KH, Chuang CH, Cheng TC, Hsieh YC, Tseng YL, Chen BM, Roffler SR, Cheng TL*. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials. 2014 Dec;35(37):9930-40 **SCI.** (Category: Materials Science, Biomaterials, IF: 8.312, Ranking: 1/32, 2013 JCR). (Equally contributed first author). MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.
27. Chuang KH, Kao CH, Roffler SR, Lu SJ, Cheng TC, Wang YM, Chuang CH, Hsieh YC, Wang YT, **Wang JY**, Weng KY, Cheng TL*. Development of an Anti-Methoxy Poly(ethylene glycol) (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules. Macromolecules 2014. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. **SCI**. (Category: in Polymer Science, IF=5.927, Ranking: 3/82, 2013 JCR).
28. Su YC, Cheng TC, Leu YL, Roffler SR, **Wang JY**, Chuang CH, Kao CH, Chen KC, Wang HE, Cheng TL. PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy. Mol Cancer Ther 2014 Dec;13(12):2852-63. MOHW103-TD-B-111-05, Biosignature in Colorectal Cancers, Academia Sinica, Taiwan. **SCI** (Category: Oncology, IF: 6.107, Ranking: 23/202, 2013 JCR).
29. Li CF, He HL, **Wang JY**, Huang HY, Wu TF, Hsing CH, Lee SW, Lee HH, Fang JL, Huang WT, Chen SH. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. J Clin Pathol. 2014 Dec;67(12):1056-61. MOHW103-TD-B-111-05. **SCI.**
30. Tsai PC, Huang SW, Tsai HL, Ma CJ, Hou MF, Wang YS, Juo SH, **Wang JY***. The association between DNA copy number aberrations at chromosome 5q22 and gastric cancer. PLoS One 2014 Sep 11;9(9):e106624. KMUH98-8I04, KMUH98-8G05, KMUH99-9R03, MOHW103-TD-B-111-05, NSC 99-2320-B-037-014-MY3, NSC 94-2314B037-104. **SCI.** (Category: Multidisciplinary Sciences, IF: 3.534, Ranking: 8/55, 2013 JCR).